Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Open in Screener

ATRC

Atricure Inc

Nov 25 • 04:00PM ET

38.48

+0.74 1.96 %

Healthcare • Medical Instruments & Supplies • USA • NASD

Peers: BSX ABT MDT EW ISRG BIO JNJ IART LMAT ZBH

| Held by: VTI IWM VB VBK VXF IWO IHI SCHA FESM VTWO

Index	RUT	P/E	-	EPS (ttm)	-0.61	Insider Own	3.71%	Shs Outstand	49.71M	Perf Week	16.04%
Market Cap	1.91B	Forward P/E	-	EPS next Y	-0.13	Insider Trans	-1.26%	Shs Float	47.87M	Perf Month	5.51%
Enterprise Value	1.85B	PEG	-	EPS next Q	-0.10	Inst Own	97.18%	Short Float	4.81%	Perf Quarter	3.16%
Income	-28.77M	P/S	3.69	EPS this Y	60.60%	Inst Trans	-1.60%	Short Ratio	4.88	Perf Half Y	14.73%
Sales	518.30M	P/B	4.01	EPS next Y	64.10%	ROA	-4.60%	Short Interest	2.30M	Perf YTD	25.92%
Book/sh	9.59	P/C	12.94	EPS next 5Y	-	ROE	-6.11%	52W High	43.11 -10.74%	Perf Year	7.85%
Cash/sh	2.97	P/FCF	59.92	EPS past 3/5Y	- -0.33%	ROIC	-5.17%	52W Low	28.29 36.02%	Perf 3Y	-16.49%
Dividend Est.	-	EV/EBITDA	171.28	Sales past 3/5Y	19.26% 15.05%	Gross Margin	74.28%	Volatility	5.54% 5.79%	Perf 5Y	-5.69%
Dividend TTM	-	EV/Sales	3.57	EPS Y/Y TTM	26.94%	Oper. Margin	-1.83%	ATR (14)	1.71	Perf 10Y	85.89%
Dividend Ex-Date	-	Quick Ratio	2.85	Sales Y/Y TTM	15.80%	Profit Margin	-5.55%	RSI (14)	66.98	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.87	EPS Q/Q	96.64%	SMA20	13.96%	Beta	1.44	Target Price	51.67
Payout	-	Debt/Eq	0.17	Sales Q/Q	15.84%	SMA50	9.58%	Rel Volume	0.97	Prev Close	37.74
Employees	1300	LT Debt/Eq	0.17	Earnings	Oct 29 AMC	SMA200	12.24%	Avg Volume	472.12K	Price	38.48
IPO	Aug 05, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	91.06% 2.29%	Trades		Volume	458,107	Change	1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-24	Resumed	JP Morgan	Overweight	$40
Apr-23-24	Upgrade	Oppenheimer	Perform → Outperform	$32
Oct-23-23	Initiated	JMP Securities	Mkt Outperform	$60
Sep-29-23	Initiated	UBS	Buy	$56
Aug-05-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Reiterated	Needham	Buy	$53 → $63
Nov-06-20	Reiterated	Needham	Buy	$63 → $53
Apr-07-20	Initiated	Oppenheimer	Outperform	$45
Feb-06-20	Initiated	BTIG Research	Buy	$42
Jan-24-20	Reiterated	Needham	Buy	$39 → $48
Aug-13-19	Downgrade	Northland Capital	Outperform → Market Perform	$30
Apr-12-19	Initiated	JP Morgan	Overweight	$37
Oct-04-18	Reiterated	Needham	Buy	$36 → $39
Aug-02-18	Reiterated	Stifel	Buy	$32 → $34
Aug-02-18	Reiterated	Needham	Buy	$32 → $36
Jun-18-18	Reiterated	Needham	Buy	$26 → $32
Apr-27-18	Reiterated	Needham	Buy	$23 → $26
Jan-16-18	Reiterated	Needham	Buy	$25 → $23
Nov-02-17	Reiterated	Needham	Buy	$26 → $25
Jul-28-17	Reiterated	Needham	Buy	$25 → $26

Show Previous Ratings

Today 09:55AM	Wall Street Analysts Believe AtriCure (ATRC) Could Rally 36.3%: Here's is How to Trade (Zacks)
Nov-20-25 09:40AM	Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-18-25 08:00AM	AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference (Business Wire)
Nov-07-25 09:35AM	AtriCure (ATRC) Loses 13.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-06-25 02:16AM	Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings (Revised) (Zacks)
09:40AM	Loading…
Nov-04-25 09:40AM	Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-29-25 05:30PM	Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings (Zacks)
05:10PM	AtriCure (ATRC) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:06PM	AtriCure: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025 (Business Wire)
Oct-28-25 09:46AM	AtriCure Inc (ATRC) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
08:00AM	AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial (Business Wire)
Oct-27-25 08:00AM	AtriCure to Participate in Upcoming Investor Conferences (Business Wire)
Oct-08-25 08:00AM	AtriCure to Announce Third Quarter 2025 Financial Results (Business Wire)
Oct-03-25 05:54AM	Medtronic wins CE mark for Penditure LAA exclusion device (MedTech Dive)
08:08AM	Loading…
Sep-09-25 08:08AM	Do You Believe in the Upside Potential of Atricure (ATRC)? (Insider Monkey)
08:00AM	AtriCure Announces the Launch of the cryoXT Device for Post-Operative Pain Management Following Amputation (Business Wire)
Aug-20-25 08:00AM	AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference (Business Wire)
Jul-30-25 03:16AM	AtriCure Inc (ATRC) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Milestones (GuruFocus.com) +10.72%
Jul-29-25 05:30PM	AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:10PM	AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:08PM	AtriCure: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure ReportsSecondQuarter2025 Financial Results; Raises Financial Outlook for 2025 (Business Wire)
Jul-28-25 08:00AM	AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference (Business Wire) +5.46%
Jul-17-25 08:40AM	Abbott (ABT) Q2 Earnings and Revenues Top Estimates (Zacks)
Jul-15-25 08:00AM	AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention (Business Wire)
Jul-08-25 08:00AM	AtriCure to Announce Second Quarter 2025 Financial Results (Business Wire)
Jun-30-25 09:40AM	Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? (Zacks)
Jun-12-25 09:40AM	Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year? (Zacks)
May-27-25 09:40AM	Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:00AM	Loading…
May-23-25 08:00AM	AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (Business Wire)
May-15-25 09:55AM	Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect? (Zacks)
Apr-30-25 08:07AM	Q1 2025 AtriCure Inc Earnings Call (Thomson Reuters StreetEvents) -13.68%
03:15AM	AtriCure Inc (ATRC) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Apr-29-25 09:34PM	AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:30PM	AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:10PM	AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:07PM	AtriCure: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure Reports First Quarter 2025 Financial Results (Business Wire)
Apr-10-25 11:37AM	LeMaitre (LMAT) Soars 7.7%: Is Further Upside Left in the Stock? (Zacks)
08:00AM	AtriCure Announces First Use of the AtriClip PRO-Mini Device (Business Wire)
Apr-09-25 08:10AM	Neogen (NEOG) Lags Q3 Earnings and Revenue Estimates (Zacks) +8.13%
Apr-08-25 12:18PM	AtriCure Drops 25%: Bargain Or Caution Sign? (Seeking Alpha)
08:00AM	AtriCure to Announce First Quarter 2025 Financial Results (Business Wire)
Mar-12-25 08:00AM	AtriCure to Host Analyst & Investor Day on March 26, 2025 (Business Wire)
Feb-13-25 12:00PM	AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know (Zacks) -6.54%
10:29AM	Q4 2024 AtriCure Inc Earnings Call (Thomson Reuters StreetEvents)
02:16AM	AtriCure Inc (ATRC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-12-25 05:30PM	Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings (Zacks)
05:15PM	AtriCure (ATRC) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:38PM	AtriCure: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results (Business Wire)
Feb-11-25 09:15AM	Exploring Analyst Estimates for AtriCure (ATRC) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-05-25 10:00AM	Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jan-23-25 06:26PM	Why AtriCure, Inc. (ATRC) Is Skyrocketing Now (Insider Monkey)
Jan-22-25 08:00AM	AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Jan-13-25 08:00AM	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst and Investor Day (Business Wire) +9.49%
Dec-23-24 08:00AM	AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-20-24 08:00AM	AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-07-24 08:00AM	AtriCure to Participate in the Stifel 2024 Healthcare Conference (Business Wire)
Oct-30-24 10:19AM	Q3 2024 AtriCure Inc Earnings Call (Thomson Reuters StreetEvents) +18.35%
03:12AM	AtriCure Inc (ATRC) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Market Challenges (GuruFocus.com)
Oct-29-24 07:00PM	AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:10PM	AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:07PM	AtriCure: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-28-24 08:00AM	AtriCure to Participate in the UBS Global Healthcare Conference (Business Wire)
Oct-15-24 08:00AM	AtriCure Announces Launch of cryoSPHERE MAX Probe for Post-Operative Pain Management (Business Wire)
Oct-08-24 08:00AM	AtriCure to Announce Third Quarter 2024 Financial Results (Business Wire)
Oct-01-24 08:00AM	AtriCure Receives CE-Mark for the EnCompass Clamp (Business Wire)
Sep-18-24 10:43AM	Heres Why TimesSquare Capital U.S. Small Cap Growth Strategy Decided to Sell AtriCure (ATRC) (Insider Monkey)
Aug-28-24 06:32AM	AtriClip FLEX-Mini device treatment begins with first patient (Medical Device Network)
Aug-27-24 08:00AM	AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip FLEX-Mini Device (Business Wire)
Aug-23-24 12:07PM	AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication (Zacks)
Aug-22-24 08:00AM	AtriCure Receives Expanded CE-Mark Indication for AtriClip Devices for the Reduction of Stroke in Patients with Atrial Fibrillation (Business Wire)
Jul-30-24 05:30PM	AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:10PM	AtriCure (ATRC) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:09PM	AtriCure: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure Reports Second Quarter 2024 Financial Results (Business Wire)
Jul-29-24 08:00AM	AtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth Conference (Business Wire)
Jul-24-24 10:14AM	AtriCure (ATRC) Gains China Approval for AtriClip LAA System (Zacks)
Jul-23-24 08:00AM	AtriCure Receives Regulatory Approval to Sell AtriClip Devices in China (Business Wire)
Jul-09-24 08:00AM	AtriCure to Announce Second Quarter 2024 Financial Results (Business Wire)
Jun-28-24 06:50AM	Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025 (InvestorPlace)
Jun-21-24 01:44AM	AtriCure (ATRC) Stock Slipped on Competition Threat (Insider Monkey)
May-31-24 07:00PM	Insider Buying: Chief Technical Officer Salvatore Privitera Acquires Shares of AtriCure Inc (ATRC) (GuruFocus.com)
May-15-24 08:00AM	AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference (Business Wire)
May-02-24 03:18PM	AtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call Transcript (Insider Monkey) -10.26%
08:36AM	Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating (MT Newswires)
03:49AM	AtriCure Inc (ATRC) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-01-24 08:57PM	ATRC Stock Earnings: AtriCure Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00PM	Compared to Estimates, AtriCure (ATRC) Q1 Earnings: A Look at Key Metrics (Zacks)
05:55PM	AtriCure Inc (ATRC) Surpasses Revenue Estimates in Q1 2024 Despite Wider Losses (GuruFocus.com)
05:30PM	AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:34PM	AtriCure: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure Reports First Quarter 2024 Financial Results (Business Wire)
Apr-30-24 08:00AM	AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference (Business Wire)
Apr-23-24 07:07AM	--Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32 (MT Newswires)
Apr-19-24 09:45AM	AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management (Zacks)
Apr-18-24 08:00AM	AtriCure Announces Launch of the cryoSPHERE+ Probe for Post-Operative Pain Management (Business Wire)

AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded in 1994 and is headquartered in Mason, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SVEN WEHRWEIN	Director	Nov 25 '25	Proposed Sale	38.00	4,967	188,746		Nov 25 04:06 PM
Yuen Maggie	Director	Nov 21 '25	Sale	35.72	3,000	107,160	11,371	Nov 25 09:01 AM
SVEN WEHRWEIN	Director	Nov 24 '25	Proposed Sale	37.32	5,033	187,854		Nov 24 05:41 PM
MAGGIE YUEN	Director	Nov 21 '25	Proposed Sale	35.72	3,000	107,158		Nov 21 05:53 PM
Noznesky Justin J	Chief Mktg & Strategy Officer	Sep 12 '25	Sale	36.30	3,000	108,900	83,964	Sep 16 08:45 AM
Noznesky Justin J	Officer	Sep 12 '25	Proposed Sale	36.30	3,000	108,891		Sep 12 02:17 PM
WEHRWEIN SVEN	Director	Aug 22 '25	Option Exercise	19.95	5,000	99,750	39,374	Aug 26 08:27 AM
WEHRWEIN SVEN	Director	Aug 22 '25	Sale	37.00	5,000	185,000	34,374	Aug 26 08:27 AM
SVEN WEHRWEIN	Director	Aug 22 '25	Proposed Sale	37.00	5,000	185,000		Aug 22 04:01 PM
WEHRWEIN SVEN	Director	Aug 19 '25	Option Exercise	19.95	5,000	99,750	39,374	Aug 21 09:04 AM
WEHRWEIN SVEN	Director	Aug 19 '25	Sale	36.00	5,000	180,000	34,374	Aug 21 09:04 AM
SVEN WEHRWEIN	Director	Aug 19 '25	Proposed Sale	36.00	5,000	180,000		Aug 19 04:12 PM
GROVES REGINA E	Director	Aug 06 '25	Sale	36.82	2,452	90,283	33,715	Aug 08 09:12 AM
Doraiswamy Vinayak	Chief Scientific Officer	Aug 05 '25	Sale	36.58	2,500	91,450	71,872	Aug 07 08:45 AM
GROVES REGINA E	Director	Aug 06 '25	Proposed Sale	36.83	2,452	90,307		Aug 06 10:38 AM
VINAYAK DORAISWAMY	Officer	Aug 05 '25	Proposed Sale	36.58	2,500	91,442		Aug 05 04:08 PM
Doraiswamy Vinayak	Chief Scientific Officer	May 28 '25	Sale	33.44	2,500	83,600	73,550	May 30 04:21 PM
VINAYAK DORAISWAMY	Officer	May 28 '25	Proposed Sale	33.44	2,500	83,600		May 28 04:02 PM
WHITE ROBERT S.	Director	May 05 '25	Option Exercise	22.62	10,000	226,200	106,773	May 07 08:25 AM
Prange Karen	Director	Mar 05 '25	Sale	38.12	6,100	232,532	17,828	Mar 07 08:21 AM
Prange Karen	Director	Mar 05 '25	Proposed Sale	38.04	6,100	232,044		Mar 05 10:02 AM

Open in Screener

PEN

Penumbra Inc

Nov 25 • 04:00PM ET

298.71

+0.60 0.20 %

Healthcare • Medical Devices • USA • NYSE

Peers: BSX ISRG EW HOLX MDT JNJ ABT SYK ZBH TFX

| Held by: IJH VTI VB VBK XMHQ VXF MDY IWP XMMO IHI

Index	-	P/E	71.38	EPS (ttm)	4.18	Insider Own	3.19%	Shs Outstand	39.15M	Perf Week	7.41%
Market Cap	11.70B	Forward P/E	59.16	EPS next Y	5.05	Insider Trans	-10.51%	Shs Float	37.91M	Perf Month	20.45%
Enterprise Value	11.44B	PEG	1.68	EPS next Q	1.09	Inst Own	94.70%	Short Float	4.80%	Perf Quarter	11.91%
Income	164.03M	P/S	8.77	EPS this Y	69.54%	Inst Trans	2.60%	Short Ratio	4.06	Perf Half Y	13.02%
Sales	1.33B	P/B	8.61	EPS next Y	34.14%	ROA	10.18%	Short Interest	1.82M	Perf YTD	25.78%
Book/sh	34.70	P/C	24.87	EPS next 5Y	42.40%	ROE	13.32%	52W High	310.00 -3.64%	Perf Year	24.21%
Cash/sh	12.01	P/FCF	76.65	EPS past 3/5Y	36.76% -23.21%	ROIC	10.51%	52W Low	221.26 35.00%	Perf 3Y	56.16%
Dividend Est.	-	EV/EBITDA	59.08	Sales past 3/5Y	16.91% 16.89%	Gross Margin	66.60%	Volatility	3.35% 3.64%	Perf 5Y	15.64%
Dividend TTM	-	EV/Sales	8.58	EPS Y/Y TTM	369.96%	Oper. Margin	12.95%	ATR (14)	9.43	Perf 10Y	519.22%
Dividend Ex-Date	-	Quick Ratio	4.18	Sales Y/Y TTM	14.61%	Profit Margin	12.30%	RSI (14)	72.86	Recom	1.55
Dividend Gr. 3/5Y	- -	Current Ratio	6.73	EPS Q/Q	54.78%	SMA20	12.63%	Beta	0.60	Target Price	312.94
Payout	0.00%	Debt/Eq	0.16	Sales Q/Q	17.82%	SMA50	15.87%	Rel Volume	1.71	Prev Close	298.11
Employees	4500	LT Debt/Eq	0.15	Earnings	Nov 05 AMC	SMA200	13.12%	Avg Volume	448.27K	Price	298.71
IPO	Sep 18, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.45% 4.03%	Trades		Volume	765,541	Change	0.20%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-25	Initiated	Wells Fargo	Underweight	$15
Oct-08-25	Upgrade	Needham	Hold → Buy	$326
Sep-02-25	Initiated	Evercore ISI	Outperform	$300
Mar-14-25	Initiated	BofA Securities	Buy	$320
Jan-21-25	Initiated	UBS	Buy	$305
Dec-17-24	Initiated	Oppenheimer	Outperform	$275
Dec-11-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$190 → $275
Sep-18-24	Initiated	Stifel	Buy	$238
Sep-03-24	Initiated	Leerink Partners	Outperform	$263
Jul-31-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$289 → $150
Jul-31-24	Downgrade	Citigroup	Buy → Neutral	$165 → $178
Feb-23-24	Downgrade	JP Morgan	Overweight → Neutral	$284 → $250
Sep-06-23	Initiated	Morgan Stanley	Equal-Weight	$265
Jul-19-23	Initiated	Robert W. Baird	Outperform	$375
Mar-29-23	Downgrade	Needham	Buy → Hold
Jan-30-23	Initiated	Piper Sandler	Overweight	$275
Nov-04-22	Upgrade	Citigroup	Neutral → Buy	$217 → $212
Oct-12-22	Initiated	Jefferies	Buy	$230
Oct-05-22	Downgrade	Citigroup	Buy → Neutral	$170 → $217
Sep-09-22	Upgrade	Needham	Hold → Buy